CIRSE Emprint Microwave Ablation Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-04

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observation of the clinical use of the Emprint Microwave Ablation System for the ablation of Liver Metastases of Colorectal Adenocarcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

NCT01815879

Colorectal Cancer Liver Metastases

UNKNOWN

"Cancersensor" Metastasis Resection

NCT01693848

Metastatic Colorectal Cancer

COMPLETED

International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE

NCT07191548

Colorectal Adenocarcinoma Metastatic in the Liver Liver Ablation Liver Cancer, Adult

NOT_YET_RECRUITING NA

Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness

NCT01816607

Rectal Diseases Rectal Neoplasms Gastrointestinal Diseases +1 more

COMPLETED

HepaSphere™ Microspheres Prospective Registry

NCT04866290

Metastatic Colorectal Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CIRSE Emprint Microwave Ablation Registry (CIEMAR) is collecting real-life data on the microwave ablation (MWA) of colorectal liver metastatic disease using the Emprint Microwave Ablation System (full study duration) or Emprint HP Microwave Ablation System (from 2021 onwards).

CIEMAR is a prospective, single-arm, multi-centre observational (non-interventional) study with the objective to observe the "real-life" use of MWA in Europe. The study is observing the use of the Emprint or Emprint HP Microwave Ablation System and all patients included in CIEMAR are receiving treatment with this device as their standard care for CRLM.

Primary endpoint: local tumour control in liver at 12 months after MWA on a per lesion basis

Secondary endpoints: Safety; Overall survival; Overall disease-free survival; Hepatic disease-free survival; Time to untreatable progression by thermal ablation; Systemic cancer therapy vacation; Quality of life; Adverse events and toxicity

In order to measure changes in the quality of life of enrolled patients at different moments in time before and after treatment with MWA, CIEMAR is collecting quality of life data using the EORTC QLQ-C30 questionnaire. Filling out the quality-of-life questionnaire is entirely voluntary for the patient. The patient will be offered to fill out the questionnaire in his/her mother tongue.

The site and patient recruitment is complete with 500 patients from 30 sites across 11 European countries. The registry is currently collecting follow-up data (until January 2026).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms Malignant Neoplasm Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Emprint Microwave Ablation System

Microwave Ablation of colorectal liver metastases

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* Proven colorectal liver metastases either histologically proven or diagnosed by imaging in a patient with known colorectal cancer
* Treated with the Emprint or Emprint HP Microwave ablation system
* Patient referred to MWA by a multidisciplinary tumour board
* Signed informed consent form
* Intention to completely treat (ablation, resection, SBRT) all visible disease within 8 weeks
* Maximum number of 9 total liver lesions
* All liver lesions must be local treatment-naive
* Maximum diameter of the largest liver lesion treated with MWA must not exceed 3cm
* Maximum diameter of lesions treated surgically may exceed this limitation
* Maximum number of 5 lung nodules eligible to be treated
* Patients may receive simultaneous liver resection and microwave ablation
* Patients may have received previous systemic therapy
* Patients must not have received surgical resection or thermal ablation for other liver lesions in the last 3 months before inclusion
* Patients treated with a liver-first approach may be included if treatment of the primary tumour is planned
* If applicable: complete response of treated rectal tumour proven by imaging

Exclusion Criteria

* Life expectancy less than 6 months (palliative treatment)
* Extrahepatic metastases with the exception of a maximum of 5 lung nodules
* Ongoing infection (viral/bacterial)
* Patients receiving simultaneous bowel surgery and microwave ablation
* Patients receiving simultaneous IRE, RFA, SBRT, Cryoablation, HIFU or other local treatment than resection
* Pregnancy
* Patients with liver metastases that cannot be completely and safely treated
* Active cancers other than CRC
* Non-resected primary colon cancer
* Advanced liver disease or evidence of liver insufficiency

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No